Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS

NCT04498403 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT04498403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04498403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3, MULTICENTER, OPEN-LABEL STUDY OF THE LONG-TERM SAFETY OF CRISABOROLE OINTMENT, 2% IN JAPANESE PEDIATRIC AND ADULT PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Terminated
Start date
September 14, 2020
Completion date
December 18, 2020
Enrollment
40 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis